This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gordon, K. A.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gordon, K. A.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2003, p. 3967-3969, Vol. 41, No. 8
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.8.3967-3969.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Commercial Broth Microdilution Panel Validation and Reproducibility Trials for Garenoxacin (BMS-284756), a Novel Desfluoroquinolone

Kelley A. Gordon,1* Paul R. Rhomberg,1 and Ronald N. Jones1,2

The JONES Group/JMI Laboratories, North Liberty, Iowa,1 Tufts University School of Medicine, Boston, Massachusetts2

Received 13 February 2003/ Returned for modification 14 May 2003/ Accepted 24 May 2003

Results from garenoxacin dry-form broth microdilution MIC panels prepared commercially (Sensititre, TREK Diagnostics) were compared to reference frozen-form MICs to ensure the validity of the longer-shelf-life product. A total of 1,078 organisms from seven major organism groups were used in this trial. All commercial MIC results were within ± one log2 dilution of reference garenoxacin values, and reproducibility trials produced identical MIC results for 90.5 to 92.1% of garenoxacin MIC comparisons. Control quinolones (ciprofloxacin and gatifloxacin) also performed at a similarly high level of accuracy.

* Corresponding author. Mailing address: The JONES Group/JMI Laboratories, Inc., 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317. Phone: (319) 665-3370. Fax: (319) 665-3371. E-mail: kelley-gordon {at}jmilabs.com.

Journal of Clinical Microbiology, August 2003, p. 3967-3969, Vol. 41, No. 8
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.8.3967-3969.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»